FDA clears GTC's ATryn, first US-approved drug made from a transgenic animal

16 February 2009

USA-based drug developer GTC Biotherapeutics' human antithrombin ATryn has been approved by the Food and Drug Administration for the prevention  and treatment of venous thromboembolism in hereditary  antithrombin-deficient patients undergoing surgery or childbirth.

Framingham, Massachusetts-based GTC predicts Atryn could earn as much as  $50.0 million in annual US sales in its first five years on the market.  On the day the agent was approved, January 6, shares in the firm rose  just 1% to  $0.83 cents in early afternoon trading.

Hereditary antithrombin deficiency is estimated to affect one in 2,000  to one in 5,000 people, half of whom may experience a thrombosis before  reaching 25 years of age and, based on a study, up to 85% may suffer a  thromboembolic event by age 50.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight